Literature DB >> 30374591

[Adjuvant radiotherapy in the multimodal treatment of resectable gastric cancer-criticism of the conclusions drawn from CRITICS?]

Robert Michael Hermann1, Hans Christiansen2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30374591     DOI： 10.1007/s00066-018-1394-z

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  8 in total

1.  Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.

Authors:  Mitsuru Sasako; Shinichi Sakuramoto; Hitoshi Katai; Taira Kinoshita; Hiroshi Furukawa; Toshiharu Yamaguchi; Atsushi Nashimoto; Masashi Fujii; Toshifusa Nakajima; Yasuo Ohashi
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

2.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Authors:  Marc Ychou; Valérie Boige; Jean-Pierre Pignon; Thierry Conroy; Olivier Bouché; Gilles Lebreton; Muriel Ducourtieux; Laurent Bedenne; Jean-Michel Fabre; Bernard Saint-Aubert; Jean Genève; Philippe Lasser; Philippe Rougier
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

3.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.

Authors:  Jeeyun Lee; Do Hoon Lim; Sung Kim; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Min Gew Choi; Tae Sung Sohn; Jae Hyung Noh; Jae Moon Bae; Yong Chan Ahn; Insuk Sohn; Sin Ho Jung; Cheol Keun Park; Kyoung-Mee Kim; Won Ki Kang
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

4.  Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.

Authors:  Sung Hoon Noh; Sook Ryun Park; Han-Kwang Yang; Hyun Cheol Chung; Ik-Joo Chung; Sang-Woon Kim; Hyung-Ho Kim; Jin-Hyuk Choi; Hoon-Kyo Kim; Wansik Yu; Jong Inn Lee; Dong Bok Shin; Jiafu Ji; Jen-Shi Chen; Yunni Lim; Stella Ha; Yung-Jue Bang
Journal:  Lancet Oncol       Date:  2014-10-15       Impact factor: 41.316

5.  Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.

Authors:  Salah-Eddin Al-Batran; Ralf D Hofheinz; Claudia Pauligk; Hans-Georg Kopp; Georg Martin Haag; Kim Barbara Luley; Johannes Meiler; Nils Homann; Sylvie Lorenzen; Harald Schmalenberg; Stephan Probst; Michael Koenigsmann; Matthias Egger; Nicole Prasnikar; Karel Caca; Jörg Trojan; Uwe M Martens; Andreas Block; Wolfgang Fischbach; Rolf Mahlberg; Michael Clemens; Gerald Illerhaus; Katja Zirlik; Dirk M Behringer; Wolff Schmiegel; Michael Pohl; Michael Heike; Ulrich Ronellenfitsch; Martin Schuler; Wolf O Bechstein; Alfred Königsrainer; Timo Gaiser; Peter Schirmacher; Wael Hozaeel; Alexander Reichart; Thorsten O Goetze; Mark Sievert; Elke Jäger; Stefan Mönig; Andrea Tannapfel
Journal:  Lancet Oncol       Date:  2016-10-22       Impact factor: 41.316

6.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

Authors:  J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

7.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

Authors:  David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

8.  TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).

Authors:  Trevor Leong; B Mark Smithers; Michael Michael; Val Gebski; Alex Boussioutas; Danielle Miller; John Simes; John Zalcberg; Karin Haustermans; Florian Lordick; Christoph Schuhmacher; Carol Swallow; Gail Darling; Rebecca Wong
Journal:  BMC Cancer       Date:  2015-07-21       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.